Immune checkpoint inhibitors (ICIs) are reshaping the landscape of cancer treatment, redefining the prognosis of several tumors. They act by restoring the cytotoxic activity of tumor-specific T lymphocytes that are in a condition of immune exhaustion. The same condition has been widely described in chronic HIV infection. In this review, we dissect the role of ICIs in people living with HIV/AIDS (PLWHIV). First, we provide an overview of the immunologic scenario. Second, we discuss the possible use of ICIs as adjuvant treatment of HIV to achieve elimination of the viral reservoir. Third, we examine the influence of HIV infection on ICI safety and effectiveness. Finally, we describe how the administration of ICIs impacts opportunistic infections.

Immune checkpoint inhibitors in people living with HIV/AIDS : facts and controversies / V. Castelli, A. Lombardi, E. Palomba, G. Bozzi, R. Ungaro, L. Alagna, D. Mangioni, A. Muscatello, A. Bandera, A. Gori. - In: CELLS. - ISSN 2073-4409. - 10:9(2021 Aug 27), pp. 2227.1-2227.13. [10.3390/cells10092227]

Immune checkpoint inhibitors in people living with HIV/AIDS : facts and controversies

V. Castelli;A. Lombardi
;
E. Palomba;G. Bozzi;R. Ungaro;D. Mangioni;A. Bandera;A. Gori
2021

Abstract

Immune checkpoint inhibitors (ICIs) are reshaping the landscape of cancer treatment, redefining the prognosis of several tumors. They act by restoring the cytotoxic activity of tumor-specific T lymphocytes that are in a condition of immune exhaustion. The same condition has been widely described in chronic HIV infection. In this review, we dissect the role of ICIs in people living with HIV/AIDS (PLWHIV). First, we provide an overview of the immunologic scenario. Second, we discuss the possible use of ICIs as adjuvant treatment of HIV to achieve elimination of the viral reservoir. Third, we examine the influence of HIV infection on ICI safety and effectiveness. Finally, we describe how the administration of ICIs impacts opportunistic infections.
immune checkpoint inhibitors; HIV; immune exhaustion
Settore MED/17 - Malattie Infettive
Article (author)
File in questo prodotto:
File Dimensione Formato  
Castelli-2021-Immune-checkpoint-inhibitors-in-peo.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 548.03 kB
Formato Adobe PDF
548.03 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/870300
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 7
social impact